Therefore, we propose the following mechanism to explain the atherosclerosis inhibitory effect of moxonidine: moxonidine inhibits the expression of inflammatory genes (e.g., IL-1, MCP-1 and TNF-α), which subsequently may inhibit the oxidation of LDL (Figure 8). Here, CCL2 is linked to atherosclerosis.